Lantern Pharma Inc. (LTRN)
| Market Cap | 40.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.75M |
| Shares Out | 10.76M |
| EPS (ttm) | -1.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,062 |
| Open | 3.650 |
| Previous Close | 3.730 |
| Day's Range | 3.640 - 3.860 |
| 52-Week Range | 2.380 - 11.990 |
| Beta | 1.55 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is... [Read more]
Financial Performance
Financial StatementsNews
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie ...
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--2nd quarter earnings release for LTRN.
Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timelin...
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
DALLAS--(BUSINESS WIRE)--Phase 2 Harmonic Trial _ Initial Patient Cohort Response Data.
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Q2 Earnings Call Save The Date.
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
DALLAS--(BUSINESS WIRE)--Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timelin...
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machi...
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven colla...
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learni...
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by H...
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced a series of important milestones related to the development, size, a...
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
DALLAS--(BUSINESS WIRE)--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers wi...
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
DALLAS--(BUSINESS WIRE)--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.
Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financi...
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights.
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--'Save the date" for Q3-2023 LTRN Earnings Call.